Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987520 | 0.86 | ACACB (0.35) | ACACBACACA | |
| SCHEMBL19231971 | 0.85 | SLC2A1 (0.36) | SLC2A1GPR84ACACBOPRM1SPHK1 | |
| SCHEMBL19232020 | 0.85 | SLC2A1 (0.36) | SLC2A1GPR84OPRM1 | |
| SCHEMBL19231989 | 0.80 | GPR84 (0.38) | SLC2A1GPR84OPRM1SPHK1 | |
| SCHEMBL19965691 | 0.79 | ALDH1A1 (0.35) | ACACBACACA | |
| SCHEMBL21755168 | 0.78 | OPRM1 (0.38) | SLC2A1GPR84OPRM1SPHK1 | |
| SCHEMBL19965679 | 0.75 | GPR84 (0.35) | SLC2A1GPR84OPRM1 | |
| SCHEMBL21755084 | 0.74 | ACACB (0.36) | SLC2A1GPR84ACACB | |
| SCHEMBL21282912 | 0.73 | TUBB4A (0.33) | ACACB | |
| SCHEMBL18885098 | 0.73 | GPR84 (0.39) | SLC2A1GPR84OPRM1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | SLC2A1 1906/4885GPR84 1928/4885ACACB 347/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | SLC2A1 1906/4885GPR84 1928/4885ACACB 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.